Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $691.00 MXN
Change Today 0.00 / 0.00%
Volume 0.0
GSKN On Other Exchanges
Symbol
Exchange
Xetra
London
Mexico
Frankfurt
As of 4:10 PM 05/21/15 All times are local (Market data is delayed by at least 15 minutes).

glaxosmithkline plc-spon adr (GSKN) Snapshot

Open
$691.00
Previous Close
$691.00
Day High
$691.00
Day Low
$691.00
52 Week High
04/15/15 - $741.50
52 Week Low
10/15/14 - $581.90
Market Cap
1.7T
Average Volume 10 Days
3.1K
EPS TTM
--
Shares Outstanding
2.4B
EX-Date
05/13/15
P/E TM
--
Dividend
$2.30
Dividend Yield
5.23%
Current Stock Chart for GLAXOSMITHKLINE PLC-SPON ADR (GSKN)

glaxosmithkline plc-spon adr (GSKN) Details

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company offers pharmaceutical products in the therapeutic areas, including respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health areas. The company’s wellness products include Panadol and Panadol Cold & Flu for headache, joint pain, fever, and cold symptoms; ENO and Tums that are immediate relief antacids; and Nicorette (US), Nicoderm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to smoking reduction and cessation. Its oral health products comprise Sensodyne to treat and prevent dental sensitivity and acid erosion; Polident, Poligrip, and Corega to enhance comfort of fitted dentures and to clean dentures; and Aquafresh for the prevention of caries, gum disease, and bad breath. The company’s nutrition products include Horlicks, a nutritional beverages and food; and skin health products comprise Physiogel, a face and body care product for dry, sensitive, and irritated skin, as well as Zovirax and Abreva to treat and prevent the onset of cold sores. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.

97,921 Employees
Last Reported Date: 02/26/15
Founded in 1935

glaxosmithkline plc-spon adr (GSKN) Top Compensated Officers

Chief Executive Officer, Executive Director, ...
Total Annual Compensation: 2.0M GBP
Chief Financial Officer, Executive Director, ...
Total Annual Compensation: 1.2M GBP
Chairman of Global Vaccines, Executive Direct...
Total Annual Compensation: $2.3M
Compensation as of Fiscal Year 2014.

glaxosmithkline plc-spon adr (GSKN) Key Developments

University of North Carolina and GSK Announce Novel Partnership to Accelerate Search for HIV Cure

The University of North Carolina at Chapel Hill and GSK announced the creation of the dedicated HIV Cure center and a jointly owned new company that will focus on discovering a cure for HIV/AIDS. This unique public-private partnership will redefine the traditional way of conducting research and create a new model to seek the breakthroughs needed to tackle an extraordinarily challenging global health issue. The HIV Cure center will be located on the UNC-Chapel Hill campus and will focus exclusively on finding a cure for HIV/AIDS. The new company, Qura Therapeutics, will handle the business side of the partnership, including intellectual property, commercialization, manufacturing and governance. Together, the HIV Cure center and Qura Therapeutics will serve as a catalyst for additional partners and public funding that will likely be needed to eradicate HIV worldwide. The collaboration is also expected to recruit and attract top talent from around the world.

Jing Ulrich Not Stand for Re-Election as Director of GlaxoSmithKline plc

GlaxoSmithKline plc announced that Jing Ulrich did not stand for re-election as directors, and stepped down from the board with effect from the conclusion of the AGM held on 7 May 2015.

GlaxoSmithKline plc Announces Board and Committee Changes

GlaxoSmithKline plc announced that Manvinder Singh (Vindi) Banga will join the Board of the company as a Non-Executive Director on 1 September 2015. Mr. Banga will succeed Sir Deryck Maughan as Senior Independent Director with effect from 5 May 2016. Sir Deryck will not seek re-election to the company's Board at the company's 2016 Annual General Meeting and will retire from the Board at the conclusion of the meeting. Mr. Banga worked for Unilever plc from 1977 to 2010 in a number of senior positions. In his last role at Unilever, he was President of the Global Foods, Home & Personal Care businesses, as well as being member of the Unilever Executive Board. He is currently a partner at the Clayton Dubilier & Rice and Chairman of the Supervisory Board of Mauser Group. The company also announced the changes to its Board Committees with effect from 8 May 2015: Urs Rohner, Non-Executive Director, has been appointed Chairman of the Remuneration Committee in anticipation of Tom de Swaan's retirement from the company's Board at the conclusion of Annual General Meeting. Mr. Rohner has been a member of the Remuneration Committee since his appointment to the Board on 1 January 2015. Lynn Elsenhans, Non-Executive Director, has been appointed Chairman of the Corporate Responsibility Committee in anticipation of Sir Christopher Gent's retirement from the Board at the conclusion of Annual General Meeting. Ms. Elsenhans has been a member of the Corporate Responsibility Committee since 1 October 2012.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GSKN:MM $691.00 MXN 0.00

GSKN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $161.39 USD -0.67
AbbVie Inc $65.58 USD -0.07
Actavis plc $301.91 USD +0.69
Bristol-Myers Squibb Co $68.32 USD -0.57
Medtronic PLC $78.01 USD -0.40
View Industry Companies
 

Industry Analysis

GSKN

Industry Average

Valuation GSKN Industry Range
Price/Earnings 7.3x
Price/Sales 3.2x
Price/Book 9.9x
Price/Cash Flow 7.3x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAXOSMITHKLINE PLC-SPON ADR, please visit www.gsk.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.